Clinical TrialMay 14, 2026, 04:22 PM
Serina Therapeutics advances SER-252 Phase 1b study; raises $21.2M
AI Summary
Serina Therapeutics announced its Phase 1b registrational clinical study of SER-252 for advanced Parkinson’s disease is underway, with TFL data from the SAD study arm targeted for the first half of 2027. The company also closed a $21.2 million private placement financing to support the advancement of SER-252. For the first quarter ended March 31, 2026, Serina reported a net loss of $6.9 million and held $24.5 million in cash and cash equivalents.
Key Highlights
- Phase 1b registrational clinical study of SER-252 in advanced Parkinson’s disease is underway.
- Targeting TFL data from the SAD study arm in the first half of 2027.
- Closed $21.2 million private placement financing in March and April 2026.
- Q1 2026 net loss was $6.9 million, compared to $4.8 million in Q1 2025.
- Operating expenses for Q1 2026 were $6.3 million, up from $5.9 million in Q1 2025.
- Cash and cash equivalents totaled $24.5 million as of March 31, 2026.
- Additional $5.2 million gross proceeds from PIPE received in April 2026.
Price Impact
More from SER